SaNOtize has initiated a Phase 2 study of its nitric oxide nasal spray (NONS) for the treatment of recurrent acute rhinosinusitis, the company said. The trial is expected to enroll 186 patients who will receive either the NO nasal spray or placebo at the beginning of an episode of sinusitis, with time to symptom resolution as a primary endpoint. Previous trials of NONS have evaluated the nasal spray for the treatment of COVID-19.
The SaNOtize nasal spray is currently marketed over the counter in a number of countries, including Germany, Israel, South Africa, and Hong Kong as either “Enovid” or “VirX” and is available by prescription in India as “FabiSpray.” Glenmark acquired Asian marketing rights for the intranasal NO in 2021.
SaNOtize CEO Steve Basta commented, “Our goal in developing the SaNOtize nasal spray is to apply the well-known antimicrobial effects of nitric oxide to treat people with upper respiratory infections. With this new clinical trial, we hope to demonstrate the effectiveness of NONS against infections that induce sinusitis episodes and provide a new treatment option for sinusitis patients.”
Read the SaNOtize press release.
